MDA-MB-453 (ATCC® HTB-131)

Organism: Homo sapiens, human  /  Tissue: mammary gland/breast; derived from metastatic site: pericardial effusion  /  Disease: metastatic carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue
mammary gland/breast; derived from metastatic site: pericardial effusion
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease metastatic carcinoma
Age 48 years
Gender female
Ethnicity Caucasian
Applications
This cell line is a suitable transfection host.
Storage Conditions liquid nitrogen vapor phase
Karyotype modal number = 90; range = 87 to 91.
The cell line is aneuploid human female, with chromosome counts in the hypo- to near-tetraploid range. Normal chromosomes N11, N13, and N17 are absent, and chromosomes N2, N6, and N12 are clearly under-represented with respect to the copy number of other normal chromosomes, while chromosome N20 tends towards over-representation. A large number of marker chromosomes are present with consistency, many of them with more than one copy. The near-diploid population of cells reported for this culture has been replaced by a tetraploid population.
Images
Derivation
MDA-MB-453 was derived in 1976 by R. Cailleau et al. from an effusion of a 48 year old female patient with metastatic carcinoma of the breast, involving the nodes, brain and both pleural and pericardial cavities.
Clinical Data
48 years
Caucasian
female

Receptor Expression

fibroblast growth factor (FGF), expressed

Tumorigenic No
Effects
No, in immunosuppressed mice
Yes, in semisolid medium
Comments
The cells overexpress FGF receptors.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

(Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation)


Subculturing Volumes are given for a 75 cmflask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C without CO2.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 100%
Temperature: 37.0°C
STR Profile
Amelogenin: X
CSF1PO: 10,12
D13S317: 12
D16S539: 9
D5S818: 11
D7S820: 10
THO1: 6
TPOX: 10
vWA: 17,18
Isoenzymes
AK-1, 1
ES-D, 1-2
G6PD, B
GLO-I, 1
PGM1, 1
PGM3, 1
Name of Depositor R Cailleau
Year of Origin June 10, 1976
References

Brinkley BR, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 7000337

Siciliano MJ, et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779

McLeskey SW, et al. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res. 54: 523-530, 1994. PubMed: 7506125

Cailleau R, et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202

Soker S, et al. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-endoded domain. J. Biol. Chem. 271: 5761-5767, 1996. PubMed: 8621443

Noonberg SB, et al. Evidence of post-transcriptional regulation of U6 small nuclear RNA. J. Biol. Chem. 271: 10477-10481, 1996. PubMed: 8631843

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
FAQ's
  1. Morphology of ATCC® HTB-131


    Date Updated: 3/27/2014

Restrictions

Unless the Purchaser has a separate license agreement with The University of Texas M. D. Anderson Cancer Center (“Institution”), the ATCC Material is subject to the following restrictions:

  1. The ATCC Material (and any Modifications, Unmodified Derivatives and/or Progeny thereof) may not be used (1) for commercial purposes or Commercial Use by any Purchaser, or (2) by for-profit or commercial entities for any purpose, provided, however, that ATCC Material that is purchased from ATCC as deoxyribonucleic acid and/or ribonucleic acid or nucleotide chains of any length (hereinafter, “Nucleic Acids”) may be used for internal research purposes by any Purchaser of Nucleic Acids;
  2. Purchaser may not transfer ATCC Materials, Modifications, Unmodified Derivatives, or Progeny to any for-profit entity or commercial entity; and
  3. Purchaser may not use ATCC Materials (or any Modifications, Unmodified Derivatives and/or Progeny thereof) in connection with any research, collaboration or other activities involving a third party that is a commercial entity or for-profit entity.

The restrictions set forth above are in addition to the restrictions set forth in the ATCC Material Transfer Agreement. Capitalized terms have the meanings set forth in the ATCC Material Transfer Agreement unless otherwise indicated above.

For instructions on how to obtain a license from Institution, please contact Dustin J. Romine, M.A. at the Institution Office of Technology Commercialization via email at dromine@mdanderson.org.

Purchaser acknowledges and agrees that ATCC will send Purchaser’s contact information and order details to Institution’s Office of Technology Commercialization.

References

Brinkley BR, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 7000337

Siciliano MJ, et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779

McLeskey SW, et al. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res. 54: 523-530, 1994. PubMed: 7506125

Cailleau R, et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202

Soker S, et al. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-endoded domain. J. Biol. Chem. 271: 5761-5767, 1996. PubMed: 8621443

Noonberg SB, et al. Evidence of post-transcriptional regulation of U6 small nuclear RNA. J. Biol. Chem. 271: 10477-10481, 1996. PubMed: 8631843